| 1557 |
National Cancer Institute |
Html |
en |
Colorectal Cancer Screening (PDQ®)–Patient Version |
There are five types of tests that are used to screen for colorectal cancer: fecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy, and DNA stool test. Learn more about these and other tests in this expert-reviewed summary. |
| PDQ Screening | 0.618949 |
| stool | 0.590523 |
| cancer treatment | 0.582023 |
| digital rectal exam | 0.64051 |
| ongoing clinical trials | 0.583111 |
| screening tests | 0.63308 |
| Different screening tests | 0.618821 |
| abnormal areas | 0.580093 |
| following PDQ summaries | 0.632044 |
| Cancer Information Service | 0.620236 |
| PDQ cancer information | 0.80153 |
| false-negative test result | 0.583041 |
| Colorectal Cancer Prevention | 0.669028 |
| positive test result | 0.639633 |
| Prevention Editorial Board | 0.62622 |
| treatment clinical trials | 0.578891 |
| National Cancer Institute | 0.708875 |
| clinical trials | 0.776593 |
| colorectal cancer screening | 0.731391 |
| PDQ documents | 0.584043 |
| tube-like instrument | 0.57905 |
| test result | 0.671884 |
| cancer information summary | 0.700249 |
| clinical trial | 0.586822 |
|
| new treatment | 0.582243 |
| breast cancer prevention | 0.604538 |
| colorectal cancer | 0.988753 |
| Cancer screening trials | 0.664201 |
| false-positive test result | 0.582754 |
| new colorectal cancer | 0.672245 |
| colon cancer | 0.621374 |
| colorectal cancer help | 0.669499 |
| fecal immunochemical test | 0.586261 |
| Cancer Care page | 0.608301 |
| PDQ database | 0.587115 |
| latest published information | 0.582352 |
| NCI’s PDQ | 0.590817 |
| virtual colonoscopy | 0.681415 |
| PDQ summary | 0.644281 |
| cancer symptoms | 0.598532 |
| NCI PDQ cancer | 0.66186 |
| tests | 0.64391 |
| cancer information summaries | 0.626981 |
| special card | 0.600211 |
| comprehensive cancer information | 0.626204 |
| occult blood test | 0.58711 |
| rectum | 0.607195 |
|
CLICK HERE |
| 1624 |
National Cancer Institute |
Html |
en |
Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of Wilms tumor. |
| wilms tumor | 0.926034 |
| treatment | 0.447725 |
| malignant tumor cells | 0.243725 |
| cancer treatment | 0.217156 |
| abdomen | 0.245624 |
| NCI-supported cancer | 0.203382 |
| cancer cells | 0.312954 |
| body | 0.284934 |
| type | 0.202622 |
| chemotherapy | 0.265514 |
| kidney | 0.420084 |
| clinical trial search | 0.271589 |
| PDQ Wilms Tumor | 0.212419 |
| clinical trials | 0.537885 |
| Wilms tumor spreads | 0.21053 |
| Wilms tumor depend | 0.213963 |
|
| clinical trial | 0.332838 |
| renal cell cancer | 0.378864 |
| combination chemotherapy | 0.254074 |
| blood | 0.211019 |
| PDQ summary | 0.204133 |
| metastatic Wilms tumor | 0.210734 |
| cancer clinical trials | 0.268102 |
| lymph nodes | 0.354558 |
| congenital mesoblastic nephroma | 0.200441 |
| anaplastic Wilms tumor | 0.26619 |
| radiation therapy | 0.416592 |
| rhabdoid tumor | 0.263616 |
| cancer | 0.757965 |
| information | 0.244245 |
| Wilms tumor cells | 0.224035 |
| childhood kidney tumors | 0.354935 |
|
CLICK HERE |
| 1654 |
National Cancer Institute |
Html |
en |
Gerson Therapy (PDQ®)–Health Professional Version |
Expert-reviewed information summary about Gerson therapy as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| complex regimen | 0.484073 |
| prescribed conventional regimen | 0.48627 |
| body | 0.480118 |
| treatment regimen | 0.476762 |
| New York City | 0.503592 |
| American Cancer Society | 0.4659 |
| normal metabolic state | 0.454242 |
| Gerson’s data | 0.572285 |
| coffee enemas | 0.55048 |
| Gerson Research Organization | 0.580725 |
| cancer information summary | 0.482421 |
| cancer therapies | 0.454018 |
| colorectal cancer | 0.455812 |
| diet regimen | 0.532413 |
| Gerson therapy | 0.918805 |
| patients | 0.555703 |
| cancer patients | 0.512802 |
| Gerson’s life | 0.570445 |
| Gerson regimen | 0.719238 |
| flaxseed oil | 0.455436 |
| diet group | 0.469079 |
| Charlotte Gerson Straus | 0.587654 |
| injectable crude liver | 0.462964 |
| gonzalez regimen | 0.487953 |
| potassium | 0.46778 |
|
| United States | 0.4578 |
| Gerson approach | 0.560315 |
| cancer cells | 0.467412 |
| 5-year survival rate | 0.480223 |
| cancer cell biology | 0.469353 |
| Gerson regimen. | 0.568736 |
| A. Pancreatic enzymes | 0.456434 |
| potassium solution | 0.46218 |
| excess sodium | 0.454821 |
| Gerson Hospital | 0.567697 |
| Gerson approach. | 0.560098 |
| National Cancer Institute | 0.466567 |
| Desiccated liver capsules | 0.461935 |
| stage I–II patients | 0.465698 |
| New York | 0.508367 |
| Gerson segment | 0.563678 |
| pancreatic enzymes | 0.529579 |
| Gerson Institute | 0.579619 |
| healthy liver function. | 0.462886 |
| Gerson diet | 0.622931 |
| crude liver extract | 0.544679 |
| melanoma patients | 0.45525 |
| cancer | 0.570183 |
| Max Gerson | 0.650691 |
|
CLICK HERE |
| 1697 |
National Cancer Institute |
Html |
en |
High-Dose Vitamin C (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer. |
| cancer treatment | 0.409014 |
| Vitamin C levels | 0.46062 |
| chemotherapy | 0.385658 |
| PDQ cancer information | 0.495143 |
| Cancer Complementary | 0.400016 |
| vitamin C therapy | 0.473688 |
| vitamin C. Patients | 0.500759 |
| vitamin C. Studies | 0.500091 |
| clinical trials | 0.625144 |
| cancer information summary | 0.452988 |
| laboratory studies | 0.446817 |
| alternative cancer therapies | 0.39781 |
| clinical trial | 0.386901 |
| high doses | 0.433559 |
| prostate cancer cells | 0.388026 |
| CAM cancer research | 0.38618 |
| ovarian cancer | 0.395778 |
| malignant mesothelioma | 0.387621 |
| High-Dose Vitamin C. | 0.544572 |
| patients | 0.543391 |
| cancer patients | 0.435773 |
| NCI PDQ cancer | 0.414799 |
| cancer information database | 0.396035 |
| effects | 0.387385 |
|
| Therapies Editorial Board | 0.399092 |
| cancer information | 0.505736 |
| treatment | 0.52957 |
| breast cancer cells | 0.389833 |
| intravenous high-dose vitamin | 0.577226 |
| Complementary Therapies Editorial | 0.414088 |
| Drug Administration | 0.422556 |
| Cancer Information Specialist | 0.391085 |
| dehydroascorbic acid | 0.390795 |
| cancer cells | 0.552348 |
| Cancer Information Service | 0.451182 |
| anticancer drugs | 0.396426 |
| high-dose ascorbic acid | 0.545315 |
| National Cancer Institute | 0.563244 |
| alternative medicine | 0.442263 |
| health care | 0.392613 |
| advanced pancreatic cancer | 0.416341 |
| high-dose IV vitamin | 0.624976 |
| vitamin C treatment | 0.515175 |
| breast cancer | 0.420605 |
| animal studies | 0.461706 |
| alternative therapies | 0.414436 |
| high-dose vitamin | 0.916436 |
| cancer information summaries | 0.396462 |
|
CLICK HERE |
| 1794 |
National Cancer Institute |
Html |
es |
El dolor y el cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del dolor como una complicación a causa del cáncer o su tratamiento. Se tratan abordajes para el control y el tratamiento del dolor relacionado con el cáncer. |
| PDQ Complicaciones | 0.575413 |
| edad avanzada.Dosis | 0.516499 |
| Physician Data Query | 0.512343 |
| Estados Unidos | 0.550291 |
| radioterapia ayuda | 0.539968 |
| siguientes tipos | 0.59269 |
| libre uso | 0.498177 |
| vÃa oral | 0.816108 |
| ¿El dolor | 0.996907 |
| largo plazo | 0.526626 |
| siguientes observaciones | 0.519179 |
| Cancer Institute | 0.496567 |
|
| siguientes exámenes | 0.600861 |
| pacientes quizás | 0.564494 |
| familia instrucciones | 0.559775 |
| sÃndrome mano-pie | 0.573945 |
| siguientes medicamentos | 0.524062 |
| siguientes momentos | 0.614035 |
| empeoramiento pasajero | 0.644072 |
| siguientes sumarios | 0.581267 |
| PDQ Acupuntura | 0.539252 |
| vÃa iv | 0.553442 |
| Institutos Nacionales | 0.504308 |
|
CLICK HERE |
| 1873 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino. |
| Obstet Gynecol | 0.426292 |
| Major FJ | 0.422403 |
| sarcomas uterinos | 0.471793 |
| cisplatin as | 0.411109 |
| Markman M | 0.40448 |
| gynecologic cancer | 0.405911 |
| prognostic factors | 0.405684 |
| Brunetto VL | 0.40512 |
| Sin embargo | 0.405423 |
| or without paclitaxel | 0.411277 |
| fase ii | 0.413551 |
| Ifosfamide treatment | 0.404047 |
| endometrial stromal sarcoma | 0.415162 |
| Radiat Oncol Biol | 0.40725 |
| siguientes puntos | 0.405418 |
| oncology group study | 0.684258 |
| stromal sarcomas previously | 0.409618 |
| patologÃa equivocada | 0.404764 |
| Barrett RJ | 0.404588 |
| Kilgore L | 0.404374 |
| recurrent or metastatic | 0.405758 |
| mixed mesodermal tumors | 0.448955 |
| Gynecologic Oncology Group | 0.969258 |
| Gynecol Oncol | 0.445429 |
| Filiaci V | 0.404525 |
|
| Beecham J | 0.404572 |
| or recurrent leiomyosarcoma | 0.405872 |
| Blessing JA | 0.5678 |
| meses vs | 0.434084 |
| Organización Mundial | 0.408363 |
| pilot study | 0.40409 |
| sarcomas mesodérmicos mixtos | 0.406902 |
| Smith MR | 0.405644 |
| as second-line chemotherapy | 0.406079 |
| or recurrent | 0.412147 |
| New York | 0.404218 |
| Peters WA | 0.405698 |
| Clin Oncol | 0.49692 |
| combination chemotherapy | 0.409211 |
| verdaderos sarcomas | 0.414072 |
| Oncol Biol Phys | 0.407314 |
| cuerpo uterino | 0.408492 |
| elementos homólogos | 0.406306 |
| estadio iii | 0.405213 |
| Rosenshein N | 0.4046 |
| stromal sarcoma | 0.431127 |
| Homesley HD | 0.404643 |
| dimethyl triazenoimidazole carboxamide | 0.404595 |
| with or without | 0.432244 |
|
CLICK HERE |
| 1895 |
National Cancer Institute |
Html |
null |
Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células pequeñas. |
|
|
CLICK HERE |
| 2001 |
National Cancer Institute |
Html |
es |
Familiares a cargo de pacientes de cáncer: funciones y desafíos (PDQ®)–Versión para profesionales de salud |
Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas. |
| etapa final | 0.435131 |
| Cancer Communication Assessment | 0.482566 |
| giving bad news | 0.42261 |
| to breast | 0.424042 |
| Sin embargo | 0.471583 |
| receiving palliative care | 0.419812 |
| American Cancer Society | 0.47018 |
| Family support | 0.41866 |
| family to breast | 0.421621 |
| CA Cancer | 0.459636 |
| Given BA | 0.442227 |
| Communication Assessment Tool | 0.434693 |
| Rose JH | 0.438883 |
| family meetings | 0.426208 |
| Estados Unidos | 0.421866 |
| Support Care | 0.447919 |
| Caregivers Based | 0.422755 |
| Palliat Care | 0.44789 |
| patients with | 0.44256 |
| Pain Symptom Manage | 0.455568 |
| Support Oncol | 0.41857 |
| Baile WF | 0.422726 |
| Family Caregiver Support | 0.426151 |
| family caregivers | 0.94013 |
| Crit Care Nurs | 0.421936 |
|
| Oncol Nurs Forum | 0.49008 |
| with family caregivers | 0.435774 |
| Care Cancer | 0.474055 |
| Cancer Facts | 0.43863 |
| Arnold RM | 0.422137 |
| palliative care | 0.565514 |
| Hosp Palliat Care | 0.420581 |
| paciente cumpla | 0.459325 |
| terminally ill patients | 0.428058 |
| Family caregiver quality | 0.42241 |
| communication skills | 0.434733 |
| cancer pain | 0.552042 |
| Crit Care | 0.427432 |
| Palliat Med | 0.438559 |
| Given CW | 0.427811 |
| breast cancer | 0.524972 |
| Arch Intern Med | 0.454734 |
| Conducting family meetings | 0.417671 |
| Baider L | 0.421555 |
| caregivers with | 0.421979 |
| placing family meetings | 0.417694 |
| Crit Care Med | 0.422158 |
| symptoms among caregivers | 0.425057 |
| cancer communication | 0.540368 |
|
CLICK HERE |
| 2038 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de piel (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| nevo atÃpico | 0.426748 |
| almacena agua | 0.428194 |
| voluntarios sanos | 0.420911 |
| filtros solares | 0.422801 |
| ropa protectora | 0.423732 |
| menor exposición | 0.423337 |
| protector solar | 0.980296 |
| protector solar ayuda | 0.457908 |
| siguientes ejemplos | 0.47268 |
| luz solar | 0.660447 |
| vitamina d | 0.429105 |
| National Cancer Institute | 0.427791 |
| piel melanoma | 0.815892 |
| Instituto Nacional | 0.448341 |
|
| lunares benignos | 0.424057 |
| antecedentes familiares | 0.421492 |
| lámparas solares | 0.426025 |
| suficientes estudios | 0.422469 |
| Physician Data Query | 0.500422 |
| radiación uv | 0.839863 |
| Estados Unidos | 0.55931 |
| vitamina b3 | 0.46569 |
| suficiente ejercicio | 0.427407 |
| prevención revisa | 0.424823 |
| PDQ Prevención | 0.445149 |
| siguientes sustancias | 0.424243 |
| radiación ultravioleta | 0.557367 |
| siguientes sumarios | 0.449523 |
|
CLICK HERE |
| 15635 |
National Cancer Institute |
Html |
en |
Step 4: Award Negotiation & Issuance |
Before a grant can be awarded and accepted, several pre-award activities must happen to formalize the partnership. Ensuring compliance with federal laws, a review of costs and a negotiation of the appropriate funding level must all happen in order to rece |
| applicant institution | 0.49498 |
| NoA | 0.545113 |
| NIH eRA Commons | 0.538439 |
| HHS requirements | 0.455116 |
| applicant’s business | 0.43403 |
| special terms | 0.42079 |
| business/administrative management perspective | 0.537644 |
| initial budget period | 0.503089 |
| grants management specialist | 0.84443 |
| subsequent budget periods | 0.62245 |
| NIH official | 0.455564 |
| multiple pre-award activities | 0.51965 |
| award | 0.677162 |
| post-award process | 0.430443 |
| Grants Administration staff | 0.556889 |
| pre-award process | 0.432795 |
| terms | 0.443034 |
| Noncompeting Award Process | 0.543798 |
| special conditions | 0.423887 |
| new recipient requirements | 0.531908 |
| research staff | 0.423565 |
| Associated F&A costs | 0.474288 |
| HHS Congressional Liaison | 0.509654 |
|
| grants management | 0.935861 |
| NIH Grants Policy | 0.596078 |
| specialized terms | 0.42458 |
| grants specialist | 0.462503 |
| categorical budget | 0.451864 |
| NCI staff | 0.518462 |
| award information | 0.450047 |
| management officer certifies | 0.491818 |
| awarding office | 0.423573 |
| HHS Payment Management | 0.546384 |
| NIH GPS | 0.461713 |
| overall scientific endeavor | 0.511733 |
| review recommendations | 0.498295 |
| Initial peer review | 0.489678 |
| grants management officer | 0.679819 |
| budget category | 0.426444 |
| NIH Office | 0.466998 |
| institute special monitoring | 0.484399 |
| policy requirements | 0.426959 |
| appropriate funding level | 0.509975 |
| pre-award negotiation process | 0.500978 |
| legally binding requirements | 0.48831 |
| award notices | 0.446172 |
|
CLICK HERE |